Sensei Biotherapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Sensei Biotherapeutics Inc's ROI in the second quarter of 2026?
Sensei Biotherapeutics Inc recorded a cumulative net loss of $-196 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -189.34%.

Within the Healthcare sector 714 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3525 to 4326.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	177.82 %	48.56 %	-49.7 %	-46.79 %	-42.97 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	180	191	19	23	28
Return On Investment (TTM)	-189.34 %	-282.8 %	-82.08 %	-77.86 %	-72.16 %
SNSE's Overall Ranking	# 4326	# 3525	# 3499	# 3750	# 3473
Seq. Investment Change TTM	58.32 %	153.9 %	-17.14 %	-16.59 %	-15.34 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-196	-184	-21	-24	-27

SNSE Company Profile >> Back to SNSE Roi Comparisons >> See Annual SNSE Return On Investment

Return On Investment SNSE's Ranking
Within:	No.
Industry	# 333
Sector	# 715
Overall	# 4326

Return On Investment Statistics
High	Average	Low
-18.54 %	-65.08 %	-282.79 %
(Mar 31 2021)		(Mar 31 2026)

News about Sensei Biotherapeutics Inc Return on Investment ROI

This article provides an examination of recent updates from Sensei Biotherapeutics regarding th...

January 8, 2025

Sensei Biotherapeutics Progresses with SNS-101 Clinical Development: Anticipates Full Enrollment by Q1 2025 : This article provides an examination of recent updates from Sensei Biotherapeutics regarding the clinical development of their monoclonal antibody, SNS-101. The analysis includes milestones achieved, strategic plans, and future expectations as outlined in their recent corporate communication. Sensei Biotherapeutics, a biotechnology company focused on developing next-generation immunotherapies for cancer, has provided a comprehensive corporate update highlighting their progress and future plans concerning SNS-101. This article aims to elucidate these developments, shedding light on the implications for the company and the broader pharmaceutical landscape. Corporate Update on SNS-101 In their latest corporate update, Sensei Biotherapeutics announced a significant milestone in the clinical development of their lead drug candidate, SNS-101, a monoclonal antibody designed to enhance the immune response against tumors. The company reported that they anticipate full enrollment in the dose expansion arm of their study by the end of the first quarter of 2025. Clinical Development Milestones The progression of SNS-101 through clinical trials is a key focus for Sensei Biotherapeutics. The anticipated full enrollment by Q1 2025 marks an important benchmark in the drug s development pathway. This milestone reflects the company s commitment to advancing SNS-101 through the necessary clinical stages to evaluate its efficacy and safety in treating cancer.

Financial Statements
Sensei Biotherapeutics Inc's II. Quarter Investments	$ 180 Millions	SNSE's Balance sheet
Sensei Biotherapeutics Inc's II. Quarter Income	$ -16 Millions	Quarterly SNSE's Income Statement
SNSE's Income by Division		See SNSE's Income by Division

SNSE Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	19	40	69	109	147
Y / Y Investment Growth	-53.27 %	-41.93 %	-37.12 %	-25.47 %	-
Net Income in Millions	-21	-30	-34	-49	-37
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-113.05 %	-75.56 %	-49.62 %	-44.45 %	-25.09 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SNSE's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SNSE's Competitors
Subscribers only: Roi for Sensei Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for SNSE's Customers

Other Ratios
SNSE's Roa	SNSE's Inventory Turnover Ratio	SNSE's Growth Rates	SNSE's Dividend Statistics
	SNSE's Profitability Ratios	SNSE's Asset Turnover Ratio	SNSE's Dividend Growth
SNSE's Roe	SNSE's Valuation Ratios	SNSE's Financial Strength Ratios	SNSE's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-08-31T19:36:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.